Study of treatment for heart disease caused by ATTR-CM
Clinical Study Protocol of Transthyroxine Protein Amyloidosis Cardiomyopathy and Its Gene Carriers
This study tests different treatments for heart disease caused by ATTR-CM to see how well they work for patients and gene carriers over time.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT04935021 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients diagnosed with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) and gene carriers. It aims to evaluate the effectiveness of various treatment approaches and conduct long-term follow-up assessments. Participants will be monitored for their response to treatment and overall health outcomes. The study is designed to gather comprehensive data to improve diagnosis and management of this condition.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-90 who have been confirmed to have ATTR-CM or are gene carriers.
Not a fit: Patients who are unable to understand the study requirements or unwilling to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options and better management strategies for patients with ATTR-CM.
How similar studies have performed: Other studies have explored treatments for ATTR-CM, showing promising results, but this specific approach may offer novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old; * Patients who have the ability to understand the test and can cooperate with investigators Exclusion Criteria: * Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors
Where this trial is running
Hangzhou, Zhejiang
- xiaohong University PAN — Hangzhou, Zhejiang, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.